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Abstract: Amyotrophic Lateral Sclerosis (ALS) is the most common late-onset motor neuron disorder,
but our current knowledge of the molecular mechanisms and pathways underlying this disease
remain elusive. This review (1) systematically identifies machine learning studies aimed at the
understanding of the genetic architecture of ALS, (2) outlines the main challenges faced and compares
the different approaches that have been used to confront them, and (3) compares the experimental
designs and results produced by those approaches and describes their reproducibility in terms of
biological results and the performances of the machine learning models. The majority of the collected
studies incorporated prior knowledge of ALS into their feature selection approaches, and trained
their machine learning models using genomic data combined with other types of mined knowledge
including functional associations, protein-protein interactions, disease/tissue-specific information,
epigenetic data, and known ALS phenotype-genotype associations. The importance of incorporating
gene-gene interactions and cis-regulatory elements into the experimental design of future ALS
machine learning studies is highlighted. Lastly, it is suggested that future advances in the genomic
and machine learning fields will bring about a better understanding of ALS genetic architecture,
and enable improved personalized approaches to this and other devastating and complex diseases.
Keywords: Amyotrophic Lateral Sclerosis; machine learning; genome-wide association studies;
GWAS; genomics; ALS pathology; gene prioritization
1. Introduction
Amyotrophic Lateral Sclerosis (ALS) is a progressively fatal, late-onset motor neuron disorder
that is predominately characterised by the loss of upper and lower motor neurons. Progressive muscle
atrophy in ALS patients leads to swallowing difficulties, paralysis and ultimately to death from
neuromuscular respiratory failure [1–3]. ALS is the most common type of motor neuron disorder,
and has peak onset at 54–67 years old, although it can affect individuals of any age [2–5].
Patients typically survive 2–5 years after the first symptoms occur, with 5–10% surviving more than
10 years [1,2,6]. A population-based study of estimated ALS incidence in 10 countries found that
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prevalence could increase more than 31% from 2015 to 2040 [4]. Thus, there is an increasing need to
understand ALS pathology and the molecular pathways involved, towards prevention or successful
therapeutic intervention.
There are two major classifications among ALS patients, based on family history: 5–10% of cases
are genetically linked, and are classified as familial, having one or more relatives that suffer from ALS,
while 90% are classified as sporadic, in which a familial history is not established, and where a genetic
cause is usually not identified [7]. However, the distinction between the two categories is not always
simple, with familial ALS-associated mutations also being present among sporadic ALS cases [3].
The extent and form of genetic contribution to sporadic ALS remains unclear, but genetic factors are
considered to play an important role in the disease pathology [3,8]. Further investigation of the genetic
architecture of both familial and sporadic cases is necessary.
In recent years, advances in high-throughput technologies have enabled the discovery of multiple
Single Nucleotide Polymorphisms (SNPs) that are associated with ALS, mainly by the application
of the Genome-Wide Association Study (GWAS) approach. GWAS aims to identify SNPs and
other types of genetic variation (such as structural variants, copy number variations and multiple
nucleotide polymorphisms) that are more frequent in patients than in people without the disease [9].
Statistical tests are carried out for disease association across genetic markers numbering from hundreds
of thousands up to millions, depending on the genomic analytical platform. The most popular
genotype-phenotype association studies use statistical models such as logistic or linear regression,
depending on whether the trait is binary (i.e., case-control studies, such as ALS versus healthy controls)
or quantitative (e.g., different scales of height). GWAS has been successful in discovering tens of
thousands of significant genotype-phenotype associations in a large spectrum of diseases and traits,
such as schizophrenia, anorexia nervosa, body-mass index (BMI), type 2 diabetes, and ALS [10–13].
Over the past decade, the discovery of significant genotype-phenotype associations has provided
new insights into disease susceptibility, pathology, prevention, drug design and personalized medical
approaches [11,14,15].
Rapid recent technological advances and great efforts in the field have led to the genomic profiling
of large ALS cohorts, providing new insights into the pathology of ALS [12]. Initiatives such as Project
MinE and dbGaP have contributed to the systematic release of ALS GWAS data [16,17]. The ALSoD
publicly available database for genes that are implicated in ALS records 126 genes, with a subset
having been reproduced in multiple studies [18]. As of July 2020, the GWAS catalogue has published
317 variants and risk allele associations with ALS [10].
The scope of this review covers genome-wide association studies that employ machine learning
approaches with the aim to understand ALS pathology through gene prioritization. A search
of PubMed and Google Scholar for the terms “amyotrophic lateral sclerosis”, “GWAS” and
“machine learning” yielded 420 results, of which 7 research papers were identified as falling into
this scope. Machine learning studies that refer to the estimation of ALS heritability, to drug
repurposing/prediction for ALS, or survival analyses, are not considered.
The review is structured as follows: first, knowledge from relevant literature about ALS pathology
and genetic architecture is summarized, then the central challenges and limitations of traditional
GWAS studies are introduced in the context of ALS, while the third section provides a brief overview
of key machine learning concepts along with a description and comparison of published feature
selection and machine learning approaches using ALS GWAS datasets. The main contribution of the
review is to outline the challenges of ALS genomic studies, summarizing and comparing how these
have been addressed by the collected research papers. Finally, the further use of machine learning as a
method to understand ALS pathology is advocated.
1.1. Current Knowledge of Molecular Pathways Implicated by the Functions of Known ALS-Linked Genes
Our current knowledge of the aetiology and the genetic architecture of ALS is still elusive.
Genetic mutations, environmental contributions, epigenetic changes and DNA damage are
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hypothesized as potential causal factors that ultimately lead to motor neuron death [19,20]. Variants in
more than 30 genes are recognized as monogenic causes of ALS [12,19,21–23]. The most frequent
monogenic cause in European populations is the intronic hexanucleotide GGGGCC (G4C2) repeat
expansion (HRE) in the C9orf72 gene [24,25]. Other genes linked to ALS with high reproducibility
include Cu/Zn superoxide dismutase 1 SOD1, fused in sarcoma FUS, and transactive response
DNA-binding protein of 43 kD TARDBP/TDP-43 [19]. The discovery of risk gene mutations has
helped to unravel the molecular mechanisms of ALS, and may lead ultimately to targeted therapy and
stratified drug discovery [19,26–28].
Numerous studies have been published aimed at explaining motor neuron death, investigating the
functional effects of specific mutations of known risk-associated genes such as C9orf72, FUS, SOD1 and
TDP-43 [23,27]. Recent systematic reviews from our group have summarised the molecular pathways
and biomarkers for which there are strong supporting evidence in ALS [19,26,27]. The molecular
pathways affected in ALS can be grouped as follows (see [27] for detailed review):
• Mitochondrial dysfunction as a direct or indirect consequence of ALS-associated gene mutations
CHCHD10, FUS, SOD1, C9orf72 and TDP-43 can lead to an increase in oxidative stress, an increase
in cytosolic calcium, ATP deficiency and/or stimulation of pro-apoptotic pathways [20,22,27,29,30].
• Oxidative stress can also be derived from a stimulation of NADPH oxidase, as observed with
ATXN2 mutations [31], or from deficiency in the elimination of Reactive Oxygen Species (ROS)
as observed with some SOD1 mutations in familial cases [27,32,33]. It then may contribute to
DNA damage. Interestingly, other mutations on the ALS-associated genes NEK1 [34], SETX [35]
and C21orf2 [36] are suspected to alter the DNA repair machinery, leading to an accumulation of
oxidative damage over time. Consequently, these events could ultimately lead to motor neuron
death [34,37].
• Disrupted axonal transport has been directly linked to a mutation in the C-terminal of the
ALS-associated gene, KIF5A [12,38], and to mutations in genes encoding for neurofilaments
(NEFH), microtubules and motor proteins (PFN1,TUBA4A, DCTN1) [27,39]. Consequently,
organelle transport, protein degradation, and RNA transport are affected, disrupting cellular
homeostasis. Similarly, axonal transport disruptions have been observed in fALS patients
harboring mutations in non-cytoskeletal-related genes such as SOD1 [38].
• Protein degradation is suspected to be a key pathway that is defective in ALS. This can be a
direct consequence of mutations in ALS-associated genes involved in proteasome activity and
the autophagy pathway, such as UBQLN2, VCP, SQSTM1/P62, OPTN, FIG4, Spg11, or TBK1 [40],
and may lead to an accumulation of misfolded and non-functional proteins [27,41]. It can also
be an indirect consequence of other mutations leading to the formation of protein aggregates
such as SOD1, FUS, TDP43, C9orf72-derived DPR - aggregates that in turn impair the proteasome
and autophagic degradation pathways [42], thus exacerbating the accumulation of misfolded
proteins. Consequently, the blockade of autophagy pathways may affect vesicle secretion [43,44].
Interestingly, some ALS-associated genes are known to be directly or indirectly involved in
exosome biogenesis such as CHMP2B [45] or C9orf72 [46], respectively.
• Glutamate-mediated excitotoxicity has been suggested to cause motor neuron deterioration,
and could be an indirect consequence of ALS-associated gene mutations such as in SOD1 or
C9orf72, resulting in an elevated level of glutamate in the cerebrospinal fluid of patients [47–49].
• RNA processing and metabolism is another key pathway affected in ALS. For example,
mutations to RNA-binding proteins encoded by FUS, TDP-43, hnRNPA1, hnRNPA2B1, and MATR3,
result in altered mRNA splicing, RNA nucleocytoplasmic transport and translation [27,50–55],
as well as in the generation and accumulation of toxic stress granules [56]. Similarly, accumulation
of toxic RNA foci can be observed in motor neurons in the context of C9orf72 mutations, and may
lead to the sequestration of splicing proteins, thus affecting RNA maturation and translation [57].
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The biogenesis of microRNA is also directly affected by mutated FUS, TDP-43, or C9orf72-mediated
DPRs, thus having an impact on the expression of genes involved in motor neuron survival [27,58].
Understanding the functional processes that drive ALS pathology has proven to be a difficult and
complex task, compounded by the heterogeneity that characterises the disease. The gene products
of the 30 or more known ALS-associated genes interact with each other, are implicated in multiple
molecular pathways, and result in multiple disease phenotypes, making functional curation and
interpretation complex [19,27]. In addition, these monogenic causes in ALS occur only in ∼15% of
sporadic ALS and ∼66% of familial ALS patients, so that more than 80% of the ALS population do
not currently have any known ALS-associated mutations [19,21]. Nonetheless, acquiring an in-depth
understanding of the molecular mechanisms and the genetic architecture of ALS could potentially
lead to the identification of multiple patient strata and therefore targeted therapies to be applied to
different subgroups of ALS patients.
1.2. The Genetic Architecture of ALS
The genetic contribution to familial and sporadic ALS has not been fully explained by
genotype-phenotype discoveries [8,25], and the known Mendelian causes of ALS represent only
a small proportion of the ALS population [19,21]. Nonetheless, estimates of heritability are high in
sporadic ALS patients - for example, 61% in a twin meta-analysis study - suggesting that genetic factors
are strongly represented in sporadic ALS and that further investigation may yet identify novel causal
variants and/or multilocus interactions that could account for this high estimated heritability [59].
So far, evidence supports a model implicating rare variants (minor allele frequency <1%) along
with non-genetic causes, such as environmental factors [3,36,60,61]. Large GWAS efforts suggest a
genetic architecture for ALS that falls somewhere in the middle of the spectrum of genetic pathology in
terms of effect size and prevalence of risk variants-i.e., an intermediate genetic architecture, lying between
conditions such as schizophrenia which have many common variants each imparting a small increase
to disease risk, and conditions such as Huntington’s disease which are caused by rare large-effect
variants located in a single gene [3,20,62,63].
Many ALS-associated variants, particularly for C9orf72, also contribute to other conditions
such as frontotemporal dementia (FTD) and cerebellar disease, suggesting that ALS is a
multi-system syndrome [3,60,61]. ALS has an established overlap with other neurodegenerative
and neuropsychiatric disorders, investigation of which could lead to insights into the understanding
of pathology [3,5,25,60,64,65]. An example of this is the degree of overlap between familial ALS
(∼40%) and familial FTD (∼25%) patients that carry the G6C4 expansion of C9orf72 [65,66].
C9orf72 hexanucleotide expansion has been associated to multiple traits including Alzheimer’s and
Parkinson’s diseases, ataxia, chorea and schizophrenia [21,67–69]. A population-based GWAS study
reported a higher prevalence of psychosis, suicidal behaviour, and schizophrenia, in Irish ALS kindreds,
which was associated with the C9orf72 repeat expansion, based on an aggregation analysis [64].
Further evidence for a shared susceptibility to ALS was provided by the greater occurrence of dementia
among first-degree relatives of ALS patients [69]. Several studies have suggested that the genetic
overlap between ALS and other neurodegenerative and neuropsychiatric disorders could also be
explained by the presence of ALS-associated pleiotropic variants that influence multiple, and in some
cases quite distinct, phenotypic traits [70–72]. One study that supports this hypothesis is that of
O’Brien et al., which shows that first-degree and second-degree relatives of Irish ALS patients have a
significantly higher prevalence of schizophrenia and neuropsychiatric diseases than healthy controls,
including obsessive-compulsive disorder, psychotic illness, and autism-the authors performed k-means
clustering and calculated the relative risk to estimate aggregation [71,73–75].
Further investigation is needed to achieve a deep understanding of ALS heritability and genetic
architecture, incorporating pleiotropic gene effects into experimental design.
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2. ALS-Specific GWAS Challenges and Limitations
So far, numerous ALS GWAS studies have been published, aiming to identify novel
ALS-associated variants through standard genotype-phenotype analyses. The first was published
in 2007, providing genomic data for 276 cases and 271 controls [76]. Technological advances have
provided the opportunity for studies with a higher number of genotyped ALS cohorts. The largest
release of ALS genomic data was published in 2018 by Nicolas et al., and identified KIF5A as a novel
ALS-associated gene; the study included a publicly-available large meta-analysis dataset of 10,031,630
imputed SNPs of 20,806 ALS and 59,804 controls as well as providing controlled access to “raw”
genomic data including SNP-arrays of 12,188 cases and 3,292 controls [12,17]. Despite that hundreds
of ALS-associated variants have been recorded in public databases such as the GWAS Catalog [10],
these associations show very little reproducibility across different studies and have not been able to
explain a large percentage of ALS heritability [3,36]; a phenomenon which is generally known as the
“missing heritability” paradox [77]. It has been proposed that SNPs contribute ∼8.5% of the overall
heritability of ALS, although it should be noted that such estimates consider only linear single-marker
effects of SNPs [36,77]. Here we outline some general GWAS limitations in the context of ALS, as well
as potential reasons why standard GWAS phenotype-genotype analysis is unlikely to fully explain the
genetic architecture of ALS.
A first general challenge in large scale genomic analyses is to ensure a high quality of the genotype
data, so that the downstream results of the experimental design reflect true biology and not artifacts.
Therefore, the collected genomic data first need to pass a comprehensive Quality Control (QC) pipeline
including multiple sample and variant QC steps [78–81]. One challenge is that each dataset has its
own specific features, thus there are not fixed thresholds for each quality-control step. For this reason,
each study needs to follow a data-driven approach, taking into consideration the distribution of each
data metric. However, there are some good practices in QC that may be generally applicable to most
studies [78,81]. For example, it is typical to follow a procedure first filtering out low quality samples
then removing poor quality markers, the order of this ensuring that as many genetic markers as possible
are kept in the final dataset. However, overly strict thresholds can lead to the loss of a substantial
proportion of samples, reducing study power. Another challenge is to ensure homogeneity of the
collected samples in terms of ancestry. This QC step is carried out by analysing the population structure
to remove ethnic outliers, and by accounting for confounding factors in later stages of the analysis,
such as a potential inner population sub-structure, usually using the first few Principal Components,
after performing a Principal Component Analysis on the homogeneous sample cohort. Also, it is very
important to check for duplicated samples and, in non-family GWAS analyses, ensure that all samples
are unrelated so that specific genotypes are not over-represented (and thereby contributing a bias to
the subsequent analysis). Identity-by-descent (IBD) is a metric that corrects for such bias and takes
into account the number of variants that a pair of individuals share.
GWAS is a single marker analysis treating each variant association as an independent event that
contributes to the phenotype. Due to this, it is a standard practice for results to be corrected under
the strict multiple testing threshold (p < 5 × 10−8) of the Bonferroni correction in order to control
for false positive discoveries (Family-wise type I errors). This threshold derives from the hypothesis
of 1,000,000 independent markers being tested under a significance level of 5%. Particularly in low
sample size studies this correction can result in a loss of power of the analysis, which may then fail to
capture a portion of potential risk variants that do not pass the significance threshold (Family-wise
type II errors) [15,82].
Univariate analyses such as GWAS that test trait association for one locus at a time are not
able to capture multilocus interactions-a phenomenon called epistasis-and the interaction of the
environment with the genome; events that could potentially account for the missing heritability of
ALS and explain the disease pathology [83,84]. The term epistasis was introduced in genetics over a
century ago by Bateson et al. [85], and genetic and evolutionary biology studies have highlighted the
importance of gene-gene interactions not only in the genetic architecture of an organism but also in
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evolution [77,86,87]. Epistasis represents non-additive events in the genome including interactions
among two or more loci that have an effect on the phenotype [88]. Several studies have highlighted
the role of epistasis in pathology, showing that SNP interactions provide a stronger association to
the disease than the participating SNPs do individually [77,84,89,90]. To understand pathology
in a complex disease such as ALS, it may be necessary to identify complex genetic interactions,
including epistatic interations [77,87]. Nevertheless, the study of multilocus interactions poses a
number of challenges, in particular the need for a high computational power as the number of tested
interactions is extremely high even in pairwise combinations. As such, multivariate computational
approaches and appropriate machine learning methods may be able to capture the potentially complex
relationships among risk variants in ALS [77,90,91].
GWAS is more successfully employed under a “common disease-common variant” hypothesis,
being of particular use in common diseases such as schizophrenia which are driven by many risk
alleles each with high frequency [92]. In contrast, ALS is a heterogeneous disease likely comprised of
multiple strata each resulting from combinations of different rare mutations and other factors. As a
result, stratum-specific mutations may each have very small effects that are diluted and thus not
captured by GWAS [3,36]. The majority of GWAS analyses have used SNP-arrays as they have until
recently had a lower experimental cost in comparison to sequencing of the exome or the whole genome.
SNP-array analyses can typically capture the effect of only common variants to the phenotype whereas
sequencing analyses identify both common and rare variants. In most SNP-array GWAS studies,
variants with Minor Allele Frequency (MAF) of <1–5% are removed from subsequent analysis as they
are generally more difficult to genotype and therefore are considered potential false positives [15,78].
Nevertheless, whole genome sequencing, custom designed exome sequencing arrays, rare variant
burden analyses and imputation approaches using large reference panels (such as the Haplotype
Reference Consortium, which contains 64,976 haplotypes), face this challenge by recovering both rare
(up to 0.1% MAF) and common variants that SNP-array platforms do not usually contain [15,93–95].
However, there is still a proportion of low frequency minor allele effects on the phenotype that cannot
yet be detected by GWAS approaches and that could also potentially explain some of the missing
heritability in ALS [3,36].
Lastly, another common GWAS challenge in complex diseases is the difficulty to distinguish
causal variants from other non-disease-associated variants that are in high linkage disequilibrium [15].
Linkage disequilibrium describes the phenomenon where an allele of a variant is inherited together
with the alleles of other variants [9]. These alleles of other variants are highly correlated and will have
very similar GWAS signals with the truly causal SNP. The majority of disease-related variants are
located in cis-regulatory regions of the genome [96], and given our limited knowledge of non-coding
genomic loci, it is even more challenging for those to discern causal SNPs from the noise. Our difficulty
to identify the causal variants in complex diseases among a pool of statistically significant associated
variants adds to the challenge of identifying molecular processes that could have a significant impact
on the disease.
Advanced machine learning prediction models trained in ALS genomic data could overcome the
aforementioned challenges, moving towards better insights into disease causality and ultimately to a
personalized understanding of ALS [15,97]. In Figure 1, we describe the basic steps of an ALS machine
learning experimental design in order to discover ALS-associated novel loci or combinations of loci,
as well as the main challenges of each step. Each of the main challenges is addressed in successive
chapters of the review, as we describe and compare the experimental design of the collected gene
prioritization studies. Some of the challenges in Figure 1 have already been mentioned, such as the
need for a large sample size that could increase the power of the study, a comprehensive quality control
pipeline to assure high quality genomic data, as well as the curse of dimensionality which is a very
common problem in genomic studies that include an extremely high number of features and especially
in studies that focus on multilocus interactions.
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Figure 1. The main challenges of an ALS machine learning experimental design.
3. Facing the Challenges
In this chapter, we outline gene prioritization approaches by which published research studies
have employed machine learning methods in order to identify and rank novel ALS-linked genes,
SNPs and multilocus interactions. First, a short introduction is made to some basic machine learning
concepts that will be useful in later discussion of the machine learning approaches that have been used.
Then, details are provided about the data representation, feature curation, and selection methods that
each study chose for their experimental design and, finally, the machine learning methods and the
overall experimental designs of each study are compared, as well as considering their results.
3.1. A Brief Overview of Machine Learning Concepts
Based on the task and the type of learning there are three main machine-learning categories:
supervised, unsupervised and semi-supervised algorithms. Supervised learning methods aim
to make predictions on unknown instances (e.g., a sample or a gene) based on known labels
(e.g., ALS/non-ALS) [98]. For instance, classification is a supervised machine learning approach,
which trains a classifier using labeled data e.g., samples/genes including a case/control label (training
set) and predicts the class of an unknown sample or gene (testing set) based on specific rules and
patterns that the classifier learned during training and testing.
In classification, it has always been a challenge to identify the input features that are most
informative and maximally affect the prediction. This domain of research is described as feature selection
research [99] and has been traditionally connected to statistical methods. More recently, with the
advent of deep neural networks, explainability and interpretability of machine learning suggestions,
predictions and decisions has become an even more acute problem. This is due to the complex nature
of the network itself, which does not clearly illustrate the connection between input (features) and
output (prediction) in a humanly understandable manner. Thus, a number of recent studies aim for
explainability in deep models [100], including visualized explanations [101].
On the other hand, unsupervised learning is performed on unlabelled data, with an ultimate
purpose to identify interesting patterns or novel sub-groupings of the data. Clustering research offers
a well-established set of unsupervised algorithms which identify patterns in a group of instances
(e.g., Genes, SNPs, ALS patients), most commonly based on notions of distance (or similarity) between
instances. Distance in such cases can be measured with metrics such as Euclidean distance or the
Pearson Correlation Coefficient [74].
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Lastly, in semi-supervised learning the prediction is carried out in positive and unlabelled data.
Semi-supervised learning is applied when information is available only on instances of a single
class (usually called “positive” instances, e.g., already known-ALS genes) but there is not sufficient
information to label the rest of the instances as “negative”. Semi-supervised learning methods can
be quite challenging when the aim is to predict novel disease-associated instances since the classifier
is trained treating potentially novel instances as “negative”. Semi-supervised learning methods are
particularly common in gene prioritization studies.
An instance in a machine learning task is an entity that the classifier is trained to predict,
for example a gene in a gene prioritization algorithm or an ALS sample in an ALS/non-ALS
patient classification task. An instance is described by a number of features (e.g., gene functional
annotations, SNP genotypes etc.), typically represented as a vector, termed feature vector. All X
instances (e.g., samples or genes/SNPs) need to have the same number of Z features (e.g., genetic
mutations or functional annotations), leading to a two-dimensional matrix K that has a size of K = X * Z.
Each instance has a specific location on a Z-dimensional space (where Z is the number of features)
and each feature has, accordingly, a specific location in X-dimensional space (where X is the number
of instances).
There are a wide variety of metrics that can be used to evaluate the performance of a machine
learning model, the choice of which depends on the nature of the task. The most popular metrics
include Accuracy, Precision, Recall, F1-score, Specificity and ROC (Receiver Operating Characteristic)
curves. Accuracy represents the fraction of true positive and true negative predictions out of the total
number of the model predictions. Precision expresses how many positive predictions of the model
were truly positive. Recall (True Positive Rate) explains the percentage of the missed true positive
predictions. Recall and Precision are both very important metrics that need to be taken into account for
the evaluation of a model’s performance. F1-score calculates the harmonic mean of those two metrics,
hence the higher the F1-score is, the better the model performed. Specificity expresses the fraction of
the negative predicted instances that were actually negative. The ROC curve is a plot of True Positive
Rate against False Positive Rate expressed as 1-Specificity. The Area Under the Curve (AUC) of ROC
is employed to calculate how well the model performed - the closer the AUC is to 1, the better the
model performed.
3.2. Recent Feature Preparation and Selection Approaches in ALS Genomic Studies
Modern analytical genomic platforms and imputation methods have led to the profiling of
samples containing up to tens of millions of genetic markers. This vast amount of genomic information
makes machine learning modelling more complicated and demanding, as it is likely that only a small
minority, if any, of markers are truly causal and associated to the disease. Thus, a first challenge in
the genomic machine learning experimental design is to deal with the curse of dimensionality using
appropriate feature selection methods [102]. Below we describe and group the feature selection and
dataset curation approaches that have been used by each study, also summarized in Table 1.
J. Pers. Med. 2020, 10, 247 9 of 28
Table 1. Details of the feature selection approaches that have been followed by each study prior to
the machine learning experiments. The “Data/Instances” column summarises the primary number
of instances before further filtering, and details about the datasets that have been used by each study.
The “Features” column refers to the initial number of features in each dataset before feature selection
and after quality control (the latter being applicable only in studies using genotype data). The “Epistasis”
column indicates whether the respective study has incorporated epistatic events (i.e., multi-locus
interactions) as a feature selection method. The “Regulatory Elements” column describes studies
that have filtered their initial dataset by including only non-coding regulatory regions. Studies that
have used prior ALS-related information (e.g., already known ALS-associated SNPs/genes, known
functional information, filtering based on an ALS versus Control genotype-phenotype association
analysis p-value etc.) in order to select and reduce their initial instance and feature space are indicated
under “ALS-linked knowledge”. Lastly, we indicate machine learning methods that were used to
select only highly informative features based on specific criteria. ML: Machine Learning, SNP: Single
Nucleotide Polymorphism, MDR: Multifactor Dimensionality Reduction, CNN: Convolutional Neural
Network, PPIs: Protein- Protein Interactions, DHS: DNase I hypersensitive sites, TFBS: Transcription
Factor Binding Sites, PCA: Principal Component Analysis, t-SNE: t-distributed Stochastic Neighboring
Embedding, UMAP: Uniform Manifold Approximation and Projection.













No No No Yes PCA,
t-SNE,
UMAP
Yousefian et al. [104] 8,697,640 SNP p-values
of 14,791 ALS cases






Yes No Yes Yes None









No No No Yes None
Yin et al. [90] 4511 cases and
7397 controls [16]
823,504 SNPs from 7,9,
17 and 22 chromosomes
Yes No Yes Yes CNN




and 211 cases/211 controls
[76,106]
No Yes No Yes MDR




and 211 cases/211 controls
[76,106]
No Yes No No MDR
Sha et al. [108] SNP pairwise
interactions
555,352 SNPs of
276 cases/271 controls [76]
No No No Yes None
The use of feature selection methods are a common strategy to reduce the high number of initial
features for machine learning models [102]. As described in Table 2, four of the seven studies used
a machine learning model as a feature selection method, in some cases using specific hypotheses or
along with a combination of other strategies that will be described later in this sub-chapter. Mantis-ml
is one example of a multi-step gene prioritisation framework which extracts a heterogeneous set of
1249 gene-annotation features mined from a large collection of databases in order to discover and rank
novel disease-related genes [103]. Each instance in this model consists of 18,626 coding genes which
are labelled as positive (seeds) or unlabelled, depending on known association to the disease, based on
information retrieved from the Human Phenotype Ontology (HPO) [109]. A number of pre-processing
steps were applied that included filtering of highly correlated pairs of features, removing features with
missing data, and imputing certain features with a low missing rate. Some exploratory analyses are
then performed (i.e., heat maps, variable distributions, etc.) in the original feature space and then three
dimensionality reduction methods are automatically applied: principal component analysis (PCA),
t-distributed stochastic neighboring embedding (t-SNE) [110], and uniform manifold approximation
and projection (UMAP) [111], in order to identify any interesting pattern(s) and linear/non-linear
relationships among the features. The gene pool is randomly split into K balanced datasets containing
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both positive and unlabelled genes. Mantis-ml can use the Boruta feature selection algorithm which
labels the features (given a decision threshold) as “confirmed”/”tentative”/”rejected” by assessing the
contribution of each feature to the prediction [103], although the entire feature space is used by default.










Vitsios et al. [103] No No No Yes Yes
Yousefian et al. [104] Yes No Yes Yes Yes
Bean et al. [105] No No No Yes Yes
Yin et al. [90] Yes Yes Yes No No
Kim et al. [91] No Yes Yes Yes Yes
Greene et al. [107] No Yes No No No
Sha et al. [108] No Yes No Yes No
Several recent studies have focused on uncovering gene-gene interactions (epistasis) that
could potentially explain some part of the missing heritability of complex genetic traits such
as ALS. However, modern genomic studies that aim to model epistatic events face considerable
challenges, demanding large computational and statistical power for the analysis of a large number of
combinations among millions of genotyped loci (even when considering only pairwise interactions).
Two of the studies -Greene et al. and Kim et al.- included epistatic events in their feature selection
approach [91,107]. Both used the wrapper method Multifactor Dimensionality Deduction (MDR)-a
non-parametric, model-free approach which reduces the feature space of multilocus combinations
by creating new single variables pooled from multiple SNP genotypes [87,112]- and then estimates
statistically significant ALS-risk pairwise interactions of SNPs. Both studies used the same datasets
and pre-processing steps to identify pairwise SNP interactions that are significantly associated with
ALS. The datasets included two sporadic ALS cohorts along with healthy controls containing 276 cases
versus 271 controls in the detection dataset and 211 cases versus 211 controls in the replication
dataset [76,106]. SNPs were filtered using a 0.2 Minor Allele Frequency cut-off and a less than 90% call
rate. Lastly, Greene et al. considered only independent SNPs in further analysis, leading to a dataset of
210,382 SNPs.
Another strategy to reduce feature space is to include only regulatory elements as features
for the subsequent machine learning experiments. Two of the studies focus only on the effect of
noncoding regulatory elements in ALS pathology. It has been shown that disease-related variants
are mostly located in cis-regulatory elements of the genome marked by DNase I hypersensitive
sites (DHSs)-zones of the genome that have been associated with elevated levels of transcriptional
activity [96]. In 2020, Yousefian et al. investigated the effect of noncoding variants in ALS [104].
Firstly, they applied a p-value threshold (p < 5 × 10−4) on SNPs from a previously published large
ALS meta-analysis GWAS dataset. The authors constructed association blocks by identifying lead
SNPs having strong ALS GWAS p-value associations and being at least 1 Mb apart from each other,
then selecting also the top 30 ALS-associated SNPs located upstream and downstream of each lead
SNP; leading ultimately to 274 association blocks [104]. They enriched their selected association
blocks with functional and epigenetic information including DHS profile data, histone modifications,
functional gene-sets from the KEGG database and TF binding sites collected from TRANSFAC and
JASPAR databases [104,113–115]. After the functional enrichment of the features, they constructed
a binary feature matrix representing whether a SNP within an association block was associated or
not with a particular functional feature [104]. The second ALS study that included only noncoding
regulatory elements was published in 2019 by Yin et al. who proposed Promoter-CNN as a feature
selection method; a convolutional neural network model (comprised of 2 convolutional layers and
two deep layers) that reduces the initial feature space by selecting only the top 8 highest performing
promoter regions among variants located on chromosomes 7, 9, 17 and 22 [90]. They assessed the
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performance of Promoter-CNN using a 9-fold cross validation. Each promoter region of each individual
was represented by a window of 64 genomic features having a value of 0,1,2 to represent the genotype
at each of these 64 loci, utilizing the genomic structure of the regions [90]. The aforementioned studies
employed the genomic structure in order to build the association blocks and the promoter regions
(see Table 1).
A popular strategy that has been used to select the initial data and then further reduce the
feature and instance space is ALS-associated knowledge (see Table 1). The most relevant study that
falls into this category is Bean et al. which modelled only previously known ALS-linked gene lists,
mining information from the literature and from disease databases, as well as including a manually
curated set of ALS-associated genes [105]. In order to reduce the feature space they performed
an enrichment test on all features and, for the predictive model, kept only those features that
are significantly enriched in the mechanism(s) of the disease [116]. Another example is Yin et al.
which before applying their Promoter-CNN model as a feature selection method, they first limited
their feature space by studying only non-additive phenomena of multiple promoters located on four
specific chromosomes (7, 9, 17 and 22), those chromosomes have being selected based on the amounts
of missing heritability that have been previously identified in ALS [36,90]. Bean et al., Kim et al.,
Yousefian et al. and Sha et al., implement multi- step algorithms in which one of the initial steps
reduces the feature space by keeping only the highest performing genes/SNPs, by assessing the
enrichment of genes in ALS [105] or by applying a specific threshold of single-marker association
analysis to ALS [91,104,108].
3.3. Experimental Design and Results of the ALS Gene Prioritization Approaches
In this section we will focus on the approach and rationale of the collected studies that aim to
understand the pathology of ALS using machine learning and probabilistic models on genomic data.
We also briefly consider the main findings of each study. Although the majority of the collected studies
aim to answer more than one research question, in this section we group studies by methodology,
based on common features of their experimental design that we considered to be the main focus in
each study. In order to avoid confusion, in Table 2 we describe the main biological focus of each study.
We investigate the reproducibility of the results of each analysis, comparing it with related literature as
well as mentioning putative novel ALS discoveries in the Discussion section.
The identified studies (see Table 1) all fall under the gene prioritization umbrella category.
In Table 3, we provide brief information about the machine learning models that have been used
in these studies (after feature selection and filtering approaches have been applied, as discussed in
the previous section, see Table 1), as well as details about the assessment and the performance of
the models.
Four of the studies included epistatic events in their experimental design, testing the hypothesis that
multilocus interactions have an effect on ALS susceptibility (see Table 2). Three studies that fall into this
category, all use the same ALS detection dataset in order to discover pairwise SNP interactions [91,107,108].
Greene et al. and Kim et al. use multifactor dimensionality reduction (MDR); a wrapper method
which performs both a feature selection and classification to predict pairwise combinations of SNPs as
high-risk and low-risk for ALS [91,107]. As proposed by [112], MDR reduces multilocus dimensions
into a one-dimensional multilocus variable, the prediction performance of which is evaluated in
classification tasks (ALS versus healthy controls) by cross validation and permutation tests. Out of
pairwise combinations among 210,382 SNPs, Greene et al. reported the pair of SNPs rs4363506 and
rs6014848 to have the highest accuracy (Acc: 0.6551) and a p-value of 0.048 after permutation testing.
Their replication dataset showed a lower accuracy (Acc: 0.5821) but with a higher statistical significance
(p-value < 0.021) [107]. Kim et al. chose the best performing MDR model for each SNP, then they
mapped SNPs to genes (including neighboring regulatory elements) and investigated their enrichment
using Gene Ontology functional terms [91]. Unfortunately, they did not report any specific high
performing pairs of SNPs in terms of MDR accuracy, nor specific genes. The statistical significance
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of each MDR model was estimated using permutation, with the highest enriched Gene Ontology
gene-sets being “Regulation of Cellular Component Organization and Biogenesis” (p-values: 0.010
and 0.014), and “Actin Cytoskeleton” (p-values: 0.040 and 0.046). The p-values for each gene-set
refer to the detection and replication dataset respectively, after multiple testing. The third study is
proposed by Sha et al. implementing a two-stage probabilistic algorithm that attempts to predict
two-locus combinations that are associated to ALS using eight epistatic and nine multiplicative
two-locus predicting models. The first step was a single-marker association test using the x2 test
statistic, keeping only the 1000 SNPs having the strongest p-values. The associations of all the two-locus
combinations of those 1000 variants were then tested using the above-mentioned seventeen models.
Three SNPs were discovered participating to two two-locus combinations: rs4363506 with rs3733242
(p-value = 0.032) and rs4363506 with rs16984239 (p-value = 0.042). Reported p-values were adjusted
for multiple testing correction using permutation. They also performed Multifactor dimensionality
reduction and Combinatorial Searching Method to identify high performing two-locus interactions,
but none of the results reached the significance threshold (see Table 3). Single locus analysis was not
able to capture the three SNPs that participate to the bi-locus interaction.
Table 3. The machine learning approaches followed by each study. Acc: Accuracy, SVM: Support
Vector Machines, LR: Logistic Regression, RF: Random Forest, DNN: Deep Neural Network, SVC:
Support Vector Classifier (SVC), CNN: Convolutional Neural Network, AUC: Area under the receiver
operator characteristic curve, CSM: Combinatorial Searching Method, Chr: Chromosome.
Study Machine Learning Models Model Assessment Performance





10-fold cross validation Stacking: Avg AUC: 0.767,
DNN: Avg AUC: 0.774,
Gradient Boosting: Avg AUC: 0.79,
RF: Avg AUC: 0.798,
SVC: Avg AUC: 0.801,
XGBoost: Avg AUC: 0.805,
ExtraTrees: Avg AUC: 0.814
Yousefian et al. [104] Convolutional Neural Network Autoencoder pre-training,
Chr 1-10: training set,
Chr 11–14: testing set and
Chr 15–22: validation set
CNN: AUC: 0.96 F1-score: 0.83
Bean et al. [105] Knowledge graph edge
prediction model [116]
5-fold cross validation Fold-Change Enrichment and random guess





Yin et al. [90] Deep Neural Network (ALS-Net),
Logistic Regression, SVM, Random Forest
and Adaboost
9-fold cross validation ALS-Net: Acc: 0.769 F1-score: 0.797
LR: Acc: 0.739 F1-score:0.728
SVM: Acc: 0.725 F1-score:0.694
RM: Acc: 0.596 F1-score:0.381
Adaboost: Acc: 0.661 F1-score:0.625
(+PromoterCNN and all 4
chromosomes combined)
Kim et al. [91] Multifactor dimensionality reduction;
using a naïve Bayes classifier
1000 permutation tests Critical Acc: 0.629
and 0.640 (replication dataset)
Greene et al. [107] Multifactor dimensionality reduction 1000 permutation tests Best SNP pairwise model: Acc: 0.6551
and 0.5821 (replication dataset); with p < 0.048
and p < 0.021 (replication dataset)
Sha et al. [108] Two-locus probabilistic models,
Multifactor dimensionality reduction,
Combinatorial Searching Method
1000 permutation tests Two-locus models:
rs4363506-rs3733242: p = 0.032
rs4363506-rs16984239: p = 0.042
MDR model:
rs4363506-rs12680546: p = 0.156
CSM model:
rs4363506-rs12680546: p = 0.2
A far more complex machine learning model for ALS patient classification, studying non-additive
interactions of multilocus promoters among four chromosomes, was published in 2019 by Yin et al. [90].
Building upon previous knowledge that the majority of the disease-associated variants in GWAS
are cis-regulatory elements, this study showed that using only the highest performing promoter
regions of 4 chromosomes as features provides enough information for successful classification
of the ALS genomic profile versus healthy controls [90]. Specifically, they applied a prediction
J. Pers. Med. 2020, 10, 247 13 of 28
model for putative ALS-related genotypes located in promoter regions, using a case-control genomic
dataset containing 4,511 cases and 7,397 controls from the Dutch cohort of ProjectMinE. A two-level
pipeline was constructed in which, as a first step, deep neural networks select the eight highest
performing promoter regions of chromosomes 7, 9, 17 and 22 having the highest accuracy in ALS
status prediction (Promoter-CNN model) and then the selected promoter regions of each individual
are combined for a final classification task (ALS-Net model). A 9-fold cross validation was used to
train both models. The authors compared their ALS-Net deep learning model to other classification
models using both the pre-selected promoter regions combined from all four chromosomes by
Promoter-CNN models, and markers from individual chromosomes. The compared classification
models included a logistic regression Polygenic Risk Score (PRS) approach [117], Support Vector
Machines (SVM) [118], Random Forest [119] and AdaBoost [120,121]. The two-tier deep learning
model showed very promising results identifying both already reported associated ALS genes and new
putative ALS markers. The results showed that ALS-Net combined with Promoter-CNN pre-selected
promoter regions produced better performance (Acc: 0.769, F1-score: 0.797) than the logistic regression
Polygenic Risk Score (PRS) approach (Acc: 0.739, F1-score: 0.728) [117], Support Vector Machines
(SVM) (Acc: 0.725, F1-score: 0.694) [118], Random Forest (Acc: 0.596, F1-score: 0.381) [119], or AdaBoost
(Acc: 0.661, F1-score: 0.625) [120,121]. They highlight that their Promoter-CNN model is a successful
feature selection method keeping only the highest performing promoters from each chromosome
individually, advancing the performance of the subsequently tested classifiers [90]. The findings
indicate that combining genomic information from all four chromosomes improves the performance
for the majority of the models, supporting further the hypothesis that non-additive events take place
in ALS pathology.
Another recent study that builds upon the hypothesis that cis-regulatory noncoding variants can
have an important effect on ALS pathology, applies a functional SNP prioritization framework using
convolutional neural networks (CNN) to make ALS rare noncoding risk-variant predictions [104].
The authors build upon a previously published deep learning CNN-based model that used functional
features in order to predict causal regulatory elements in complex diseases [122]. They tested their
proposed method on a large GWAS meta-analysis cohort including 8,697,640 SNP p-values for 14,791
ALS patients and 26,898 healthy controls [12]. The functional SNP prioritization framework followed
a multi-step procedure starting from (a) collecting the upstream and downstream flanking regions
of the 274 highest GWAS ALS-associated variants, then (b) functionally annotating the variants
(including DNase I hypersensitive sites (DHSs), histone modifications, target gene functions, and
transcription factor binding sites (TFBS)) and finally (c) training the CNN model on these association
blocks with uncertain class labels using chromosomes 1–10 as a training set, chromosomes 11–14 as
a testing test and finally 15–22 as a validation set [104]. The CNN model used two convolutional
layers; the first layer measured how well each individual SNP matched the pattern of 50 functional
features using a rectified linear unit (ReLU), and the second level output prediction scores for each
SNP with a 0–1 range, with values close to one indicating that there are common regulatory patterns
embedded for a particular SNP. The CNN model shows a high predictive performance (AUC = 0.96 and
F1 = 0.83). A random forest classification for the ALS cell-type specificity showed that a high portion
of their ALS selected features have neuronal cell-type specificity within Trancriptional Factor binding
sites. The proposed framework highlights two potentially functional ALS-risk variants rs2370964
(chromosome 3, located in enhancer site of CX3CR1) and rs3093720 (chromosome 17, intron variant
in TNFAIP1). An eQTL analysis was performed to investigate the effect of these two variants on the
expression of other genes. The analysis showed that the two noncoding variants may impact ALS
risk by affecting the expression levels of CX3CR1 and TNFAIP1. The CX3CR1 gene deletion has been
associated with microglia neurotoxicity and neuron loss in transgenic ALS mice [123,124]. TNFAIP1 is
an apoptotic protein which has been associated to neurotoxicity [125]. The rs2370964 variant also
affects the CTCF and NFAT binding sites [104]. Mutations in CTCF gene has also been related to
microglial dysfunction, among other effects [126]. NFAT is a transcription factor that is involved with
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the regulation of pro-inflammatory responses in cultured murine microglia [127]. The rs3093720 SNP
affects the NR3C1 binding site, a gene which has been associated with neurodegeneration and multiple
sclerosis [128].
The accumulation of large amounts of ALS multi-omic data, functional annotations,
and tissue-specific information, has provided a great opportunity and challenge for researchers to
combine these in ways that could potentially lead to stronger machine learning models. Two collected
studies combine known ALS genes and ALS-related information mined from a variety of databases to
predict novel disease-specific genes and rank them. The first one is, Mantis-ml, a recently published
multi-step disease agnostic gene prioritisation pipeline which employs known disease-associated
genes to predict scores for putative novel genes based on feature pattern similarity [103]. As mentioned
in Section 3.2, the disease-related gene information is extracted from multiple databases and resources,
including tissue- and disease- specific data [103]. Depending on the users’ disease-related queries,
the pipeline follows automatic feature selection and pre-processing as well as an exploratory data
analysis on disease-related features. A repeated stochastic semi-supervised model is used to iteratively
predict disease-related probabilities for each gene, and then rank each gene based on the mean
prediction probability of all iterations. The starting point for the modelling is the labelling of
an entire coding gene pool (18,626 genes) based on disease relevance retrieved from the Human
Phenotype Ontology (HPO), with positive and unlabelled genes then being split into random balanced
datasets [109]. They evaluate the performance of their classifier using a stratified 10-fold random split
in every balanced dataset, which is followed by testing using the out-of-bag k-fold method. The model
generates gene prediction probabilities belonging to the respective testing set of each k-prediction
cycle. Lastly, the model calculates an aggregated prediction probability combined from all iteration
cycles. The classification performance of Mantis-ml was assessed using seven different supervised
models (gradient boosting, random forest, extra trees, extreme gradient boosting, support vector
classifier, deep neural networks, and a stacking classifier) with 10 stochastic iterations and 10-fold cross
validation in three diseases. All models showed similar performance (AUC: 0.83–0.85), with Extra
Trees having the highest mean Area Under Curve for ALS (AUC = 0.814) (see Table 3). For ALS, 77
positively labelled genes were selected, having an average AUC of 0.814 (combined from 7 classifiers).
Among the top 50 genes there were two already known ALS associated genes, FUS and L1CAM.
Specifically, “MGI mouse knockout feature” was ranked as the top feature for ALS, including human
orthologue mouse genes that have been associated with survival and developmental pathways.
Unlabelled genes (i.e., genes not annotated to ALS in the HPO) were also identified as being predictive
of ALS. Some of the top novel predicted genes among 5 out of 6 classifiers are SYNE1, ALDH5A1,
ABCA1, DNMT3A, NF2, SZT2, ACADVL, MED12, TSC2, EP400, RYR2, VCL and BBS2. SYNE1 causes
recessive ataxia and has been associated with motor neuron degeneration and ALS [129]; ALDH5A1
has been identified as significantly down-regulated protein in ALS murine models [130]; ABCA1 has
been linked with damage of neuromuscular junctions and identified in significant clusters of altered
frontal cortex genes in ALS samples [131,132]; a DNMT3A isoform has been identified in synapses and
in mitochondria and has been associated with degeneration in motor neurons in ALS patients and
abnormal expression levels in skeletal muscle and spinal cord of presymptomatic ALS mice [133,134].
Another study that combined genomic data with other types of data sources to increase the power
of the machine learning gene prioritization method was that of Bean et al., integrating functional
annotations, known ALS-gene associations, and protein-protein interactions [105]. Protein-protein
interaction networks have been useful to decipher new disease mechanisms, as proteins that are encoded
by disease-related genes are likely to interact with proteins that are implicated in similar pathologies [135].
These authors used a previously published knowledge graph-based completion model [116], which is
trained combining protein-protein interactions data mined from Intact [136,137], known disease-gene
lists from DisGeNet [138,139] and functional gene-sets from the Gene Ontology [140] in order to
make predictions of novel ALS-linked genes [105] (see Table 1). The algorithm starts by building a
knowledge graph containing known ALS data represented as nodes and their interrelationships as
J. Pers. Med. 2020, 10, 247 15 of 28
edges. The aim of the model is to predict the missing edges of the graph that could represent novel ALS
genes, providing a predictive score to each. This is a similarity score deriving from the profile which
is built by the trained knowledge graph model comparing the ALS-known genes to the rest of the
genes. They train 5 models for 5 input sets of ALS-linked genes mined from the ALS Online Database
(ALSoD), which is intended to host all known ALS- associated genetic variants [18], from the ClinVar
database of curated clinical variants [141], from DisGeNet [138,139], and a manual curated ALS gene
list generated by the authors [105] (see Table 1). For the training and testing of the model, 5-fold cross
validation was used to estimate how well the model would have predicted known ALS genes. As seen
in Table 3, all models-except the DisGeNet list- performed very well in each fold above the random
baseline, with the manual list being on top. In total, the 5 models predicted 45, 176, 192, 327 and 575
novel ALS for the Manual list, DisGeNet, ClinVar, ALSoD and union ALS-known lists, respectively.
All predicted novel genes of the manual list were also present in the other 4 lists. The authors also tested
the functional enrichment of the predicted genes following an overrepresentation analysis using Gene
Ontology terms, with all gene-sets having statistically significant enrichment to ALS-specific biological
processes, like mitochondrial activity, endosome transport and vesicular trafficking, lipid metabolism
and others. To validate the relevance of the predicted ALS genes, a gene-set and gene-level analysis
was performed using MAGMA [142] on a large ALS meta-analysis GWAS dataset (European cohort,
including 20,806 cases and 59,804 controls) [12], keeping only the variants that mapped to the putative
ALS-genes. Only ClinVar predicted genes had statistically significant results (p-value = 0.038), followed by
the Manual model which did not pass the Bonferonni correction but it was close with a p-value of 0.060.
4. Discussion
Here we identified gene prioritization machine learning studies aimed at the understanding of
genomic data in ALS, outlining the main challenges faced by such studies. We compared these studies
in terms of their feature selection methods, experimental design, machine learning performance and
their biological results. In Figure 2, we summarize some of the key decision making steps taken by
machine learning approaches in ALS genomics, and examples of some possible choices at each step.
In gene prioritization studies, the initial number of potentially “novel” SNPs/genes or,
more problematically, the potential novel multilocus combinations, can be so high as to make
computational analysis unfeasible (see Figure 1). In this context, it was intriguing to group and compare
the chosen dimensionality reduction approaches in each study. As seen in Table 1, most studies handled
this problem quite differently. More than half used a machine learning method for feature selection,
along with one or more biological hypotheses for additional filtering of the input variables. The most
common approach of biological hypothesis filtering was to infer ALS-specific knowledge early in the
experimental design. This is both an advantage and a potential disadvantage as it makes the results
more likely to have biological relevance but at the same time risks introducing bias to later stages of
the machine learning approach. An example of a feature selection method that fell into this category is
an early SNP-filtering approach based on a specific threshold of ALS GWAS p-values. This approach
succeeds in a straightforward way to reduce the feature space, but comes at the cost that potential
GWAS false positives could be inferred and/or that true positives (not captured by GWAS) might
be removed from further analysis. This may be especially problematic in the capturing of epistatic
events, as traditional GWAS analysis is a linear single-marker analysis, so filtering based on single
SNP-disease association p-values could risk losing putative significant multi-locus interactions in later
stages of the analysis [143,144]. However, a large cohort size could increase the power of a standard
GWAS analysis utilized as a feature selection method in a machine learning study.
J. Pers. Med. 2020, 10, 247 16 of 28
Figure 2. Some of the key decision making steps taken by machine learning approaches in ALS
genomics, and examples of some possible choices at each step. These included data collection,
data representation, selection of the Machine Learning algorithm for the classification task, and the
types of result obtained by the model. The studies collected information from a variety of databases
in order to mine, among other things, data on genotypes (e.g., dbGaP, GWAS Catalog, gnomAD),
functional annotations (e.g., KEGG), and Protein-Protein Interactions (e.g., STRING). Depending on
the purpose of the experimental design, the collected studies modelled genes, SNPs, cis-regulatory
regions, multilocus interactions, and/or ALS/non-ALS patients. Each instance was described using
features such as Genomic, Epigenomic, and Proteomic data, functional annotations, and/or prior
ALS-related knowledge (e.g., ALS gene-sets). Various machine learning algorithms were selected
for the classification tasks. Lastly, we visualize the distinction between the modelling results of
gene prioritization and multilocus interaction prioritization studies. Gene prioritization studies
aim to identify significant ALS associated instances (e.g., SNPs, genes and cis-regulatory regions),
whereas multilocus interaction prioritization studies aim to discover significant interactions among
multiple loci. Lastly, we note that an ALS versus non-ALS sample classification experiment can be used
to prioritize genes if the interpretability of the chosen model permits the identification of informative
genomic features.
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Deep learning seems a promising machine learning method for ALS gene prioritization studies,
as well as in ALS patient classification. Deep learning methods are known to perform well in
regulatory genomic classification tasks, being able to incorporate information from the structure of the
genomic data and capturing non-linear relationships and patterns of multilocus interactions [145,146].
This statement is further validated by comparing the performance of three collected ALS gene
prioritization studies. More specifically, three recent studies that employ deep learning as at least one
of their classification methods had very good predictive performance [90,103,104], as summarized in
Table 2. Yin et al. showed that deep neural networks perform better than other methods in classifying
ALS versus healthy controls, not only in terms of accuracy (0.769) and F1-score (0.797), but also with
an excellent recall of 0.908, using a 9-fold cross-validation [90]. Moreover, all of the benchmarked
classification methods showed improved performance when promoter selection Convolutional Neural
Network models (Promoter-CNN) where incorporated as an extra feature selection stage with the
classification models. Yousefian et al. constructed a semi-supervised Convolutional Neural Network
model in order to predict ALS-associated non-coding variants using epigenetic features. The model
showed an excellent performance achieving an AUC of 0.96 and F1-score of 0.83 [104]. This study did
not include benchmarking against other machine learning models, and interestingly the association
blocks of non-coding variants that were constructed for training, testing, and validation sets of the
model were separated into chromosome numbers 1–10, 11–14 and 15–22, respectively, rather than the
cross validation methods typically employed by other studies. Lastly, Vitsios et al. benchmarked their
proposed multi-step non-disease specific gene prioritization pipeline assessing the performance of
seven classifiers using 10-fold cross validation in three diseases. In ALS, all classifiers achieved very
similar performance with an average AUC ranging from 0.767 to 0.814, with Deep Neural Networks
achieving an average AUC of 0.774 and Extra Trees classifier being at the top [103]. Even though,
the majority of the ALS collected studies show that deep learning yields very good classification results,
one very popular challenge in such learning algorithms is the lack of explainability in the model’s
results, identifying which features are the most informative to the classification task.
In terms of reproducibility, comparing the highest ranked genes and SNPs, as well as the
reported statistically significant functional pathways, it is noteworthy that the sALS-associated variant
rs4363506 (initially identified by Schymick et al. with an empirical p-value = 10−6 [76]) was found
by both Greene et al. and Sha et al. to have statistically significant pairwise interactions with other
variants. Specifically, Greene et al. reported rs4363506 to interact with rs6014848 (Acc of 0.6551 and
a p-value < 0.048 in the detection dataset, and Acc of 0.5821 and p-value < 0.021 in the replication
dataset) and Sha et al. found that rs4363506 participated to two separate two-locus interactions: one
with rs3733242 (p-value = 0.032) and another with rs16984239 (p-value = 0.042) [107]. These were the
only significant pairwise combinations identified by either study. The replicated SNP rs4363506 is an
intergenic variant (chr10:127476239, GRCh38.p12) located between DOCK1 dedicator of cytokinesis
1 and NPS neuropeptide S [147]. DOCK1 is implicated in neural growth and is a member of the
KEGG pathway term “Regulation of actin cytoskeleton” and NPS in “positive regulation of synaptic
transmission, glutamatergic” (GO:0051966) and “regulation of synaptic transmission, GABAergic”
(GO:0032228), among others, all processes that are linked to ALS (see Section 1.1) [113,148]. This is
consistent with other work implicating the actin cytoskeleton in ALS, including the finding of the third
study, Kim et al.-investigating the functional enrichment of pairwise interactions in sporadic ALS-of
statistical significance of the Gene Ontology term “Actin Cytoskeleton” (p-value = 0.040). However,
it should be kept in mind that all 3 of these studies are analyses of the same primary dataset.
There could be several reasons for the disparity in the results of Greene and Sha et al.
(i.e., the identification of different interaction partner SNPs to rs4363506). One reason could be
that different quality control methods and thresholds are applied to the genomic datasets. In addition,
Greene et al. investigated the pairwise combinations of 210,382 uncorrelated SNPs (keeping only
independent SNPs in terms of linkage disequilibrium) using their proposed MDRGPU model,
whereas Sha et al. tested the pairwise combinations of the top 1000 SNPs with a significant
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ALS-association p-value, before testing for significant interactions using a series of different two-locus
probabilistic models. The significant results of these studies also differed in the design of the predictive
model used, with Greene et al. using Multifactor Dimensionality Reduction (MDR)-a non-parametric
method combining feature engineering and then classification which does not make any assumption
about the underlying genetic mechanisms-and Sha et al. using two-locus probabilistic parametric
models which tested specific hypotheses about the type of the genotype interaction, taking into account
the order of the genotypes in terms of penetrance of high-risk variants. Asides from the two-locus
probabilistic models, Sha et al. did in fact also test (separately) an MDR and a Combinatorial Searching
Method-unlike Greene et al., these analyses did not identify any significant pairwise combinations but,
interestingly, SNP rs4363506 was present in a pairwise combination in both models that almost passed
the threshold of statistical significance. Lastly, Kim et al. followed a multi-level approach starting
from SNP pairwise interaction feature selection, moving to testing genes associations and gene-set
functional associations to ALS. Unfortunately, they did not report any results about the MDR predicted
pairwise interactions, hence we cannot make a direct comparison with the other two studies.
From the comparison of the most statistically significant genes and SNPs predicted from the
optimally performing machine learning models of Mantis-ml [103], the knowledge graph completion
model [105], the Promoter-CNN model [90], and the non-coding variant CNN model [104], we note
several points. First, we compared the top 50 ALS genes predicted from the Mantis-ml model using
Extra Trees-the highest performing classifier of the ALS data [103]-with the top 45 performing genes
predicted by the knowledge graph-based machine learning approach using the highest performing
model trained on the manually curated ALS-linked list [105]. SLC1A2 (solute carrier family 1 member
2) was the only gene that was predicted by both approaches. SLC1A2 protein is the dominant
transporter that clears the extracellular neurotransmitter glutamate in the synapses, expressed by
astrocytes [149]. The down-regulation of SLC1A2 has previously been associated with excitotoxicity
leading to motor neuron degeneration and therefore contributing to ALS pathology, as described
in the introduction (see Section 1.1) [47,48,150]. The Mantis-ml ALS model top predicted genes
also had an overlap with the genes associated with the top performing promoters predicted by
the Promoter-CNN model [90], but only in terms of shared protein families: within the top 8
promoter regions that Promoter-CNN selected for chromosomes 7, 9, 17, and 22, there were two
promoter regions that were associated with genes LAMB4 (laminin subunit beta 4) and TRIM16
(tripartite motif containing 16); while among Mantis-ml highest predicted ALS genes were LAMB3
(laminin subunit beta 3) and TRIM28 (tripartite motif containing 28). The Laminin family contains
heterotrimeric glycoproteins of the extracellular matrix that are associated with processes such as
adhesion, survival, neuronal development and proliferation [151]. LAMB4 is implicated in tissue
development and cell migration, and has been associated with different types of cancer [140,152].
Interestingly, a laminin-4 isoform is expressed in neuromuscular junctions and has been associated with
muscular dystrophy [151]. A recent study of LAMB3 upregulation implicates this gene in cell apoptotic,
proliferating and metastatic events in patients that suffer from pancreatic cancer [153]. TRIM16 has
been associated with autophagy, degradation of protein aggregates and ubiquitination of misfolded
proteins; pathways that have been previously associated with ALS (see Section 1.1) [154]. Finally,
TRIM28 encodes a co-repressor protein which is expressed in the human brain and is a major regulator
of transposable elements [155]. Elevated transcription of transposable elements has been linked with
neurological disorders, including ALS, as well as binding to the ALS-associated RNA-processing
protein TDP-43 [156].
It is noteworthy that the vast majority of the overlapping genes that we identified among all
the collected studies are implicated in previously known ALS-associated functional pathways (as we
outlined in Section 1.1) as well as the majority of the highest predicted novel genes (as described in
Section 3.3). Nevertheless, we did not observe any further overlap among the other studies in terms
of ALS-predicted genes. Limited reproducibility among the four studies could be due to multiple
factors that derive from a number of differences in their experimental design and the focus of each
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study (see Tables 1–3). As summarised in Table 1, these four studies all use different instances,
features and feature selection methods. As far as the machine learning models are concerned, the best
performing machine learning models which were utilized for comparison were different. However,
the low reproducibility could also derive from a more general challenge of gene prioritization studies,
which concerns the difficulty of identifying the truly causal genes out of a usually large pool of novel
predicted genes that pass a chosen significance threshold [157]. The difficulty of reproducibility is
also emphasized in Bean et al. where 5 known ALS-linked gene lists mined from different databases,
and one which was manually curated, were used, with each yielding very different results even with
the same model, highlighting that the methodology and results of each study should be compared
with caution [105]. Lastly, we need to mention that due to the high number of potential novel genes
among all the benchmarked models of each study, we only compared the top genes/SNPs predicted
by the highest performing model in each case. Hence, due to this limitation, we acknowledge the
possibility of a larger existing overlap of the top genes predicted by the rest of the well performing
models that were benchmarked among the studies. These challenges, makes the identification of the
ALS implicated functional pathways even harder as well as the task of investigating reproducibility in
different studies (see Figure 1) [157,158].
We also note that several studies incorporated prior ALS biological knowledge and functional
annotations into the general experimental design (see Table 2), and the trained models showed a very
good predictive performance (see Table 3). Specifically, as seen in Table 1 all of the considered studies
except Greene et al. used an ALS-linked knowledge feature selection method to reduce their feature
space as well as the number of instances (i.e., genes and SNPs). Moreover, Bean et al., Vitsios et al. and
Yousefian et al. include ALS- specific and generic biological knowledge into their initial feature space,
such as tissue/disease-specific features and known ALS disease-gene associations, as well as gene
functional annotations, epigenetic features and protein-protein interactions (see Table 1). The most
characteristic study that falls into this category is the one of Bean et al., where the instances were only
ALS-linked lists from various resources, and the model was an ALS knowledge-based graph which
uses the neighborhood of genes and enrichment tests to define significance of association, trained using
PPIs, ALS-gene associations and functional annotations, showing the highest performance using a
manually curated ALS-linked gene list.
Multilocus interactions may have a significant role in ALS and should be considered in future ALS
genomic studies [90,91,107]. Each of the studies that investigated multilocus interactions has highlighted
that the statistically significant variants could not be replicated in single-locus analyses [90,91,107,108].
Yin et al. carried out the most complex study in this category, using a large ALS cohort (see Table 1) followed
by a thorough quality control -this was the first ALS multilocus study to investigate complex non-additive
events in such a large scale of input variables. The results provided further support for the involvement
of non-additive genetic interactions in ALS, showing that combining the genomic structure from
multiple cis-regulatory elements (in this case promoters located in different chromosomes) yields
very promising results in ALS patient classification [36,90]. Also, related literature supports that the
“missing heritability” in genetic traits could be uncovered and explained to a significant degree by
a network of gene-gene interactions which is not taken into account in the methods typically used
to estimate the proportion of heritability that is missing [77,144,159]. Even though, the prediction
of novel disease-specific gene-gene interactions poses, as described in previous chapters, a greater
number of challenges than single-marker GWAS, it offers the potential to understand the heritability
and genetic architecture of complex traits like ALS disease in greater depth. These challenges could be
faced using machine learning approaches.
Machine Learning is a rapidly evolving field that has great potential in helping us to
understand the complexity of ALS genomics, and how this relates to molecular pathways. However,
further advances are needed in GWAS machine learning approaches in order to fully uncover the
underlying mechanisms of this deadly disease which ultimately may lead us to successful personalized
disease and drug-targeting prediction approaches.
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